4 Healthcare Stocks With FDA Approvals on the Horizon

In 1992, Congress passed the Prescription Drug User Fee Act (PDUFA) allowing the U.S. Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the drug review and approval process. To promote getting novel medicines to patients expeditiously, the act requires the FDA to make its decisions within certain deadlines.

These PDUFA dates provide crucial timing information for biotech investors since FDA approval or lack thereof can create tremendous swings in stock price. Let's explore four companies with PDUFA dates lined up in the first quarter of 2020.

Image source: Getty Images.

Continue reading

Source Fool.com